Key result
Using hs-cTnI instead of CK-MB to define periprocedural MI increased event rates (13.5% vs 1.8%) but was not associated with 1-year mortality (HR 2.04; 95% CI 0.94-4.45; P=0.072).
Why the study?
It was unclear whether the type of cardiac biomarker used for diagnosing SCAI periprocedural MI affects event frequency and clinical outcomes in patients undergoing elective PCI.
Does the use of hs-cTnI compared to CK-MB for defining SCAI periprocedural MI affect the prognostic relevance for all-cause death in patients undergoing elective PCI?
Cohort (n=1,010)
Does the use of hs-cTnI compared to CK-MB for defining SCAI periprocedural MI affect the prognostic relevance for all-cause death in patients undergoing elective PCI?
Hazard Ratio: 2.04 (95% CI 0.94–4.45)
p-value: p=0.072
Using hs-cTn instead of CK-MB for diagnosing periprocedural MI after elective PCI increases event frequency but lacks prognostic relevance for 1-year mortality unless accompanied by CK-MB elevations.
hs-cTnI redefinition of periprocedural MI should not yet alter practice; hypothesis-generating for combined biomarker thresholds in elective PCI.
BACKGROUND: Periprocedural myocardial infarction (MI) according to the Society for Cardiovascular Angiography and Interventions (SCAI) criteria has prognostic relevance among patients undergoing percutaneous coronary intervention (PCI). However, it is unclear whether the type of cardiac biomarker used for the diagnosis of periprocedural MI plays a role in terms of event frequency and outcomes. OBJECTIVES: To compare the characteristics of SCAI periprocedural MI based on creatine kinase-myocardial band fraction (CK-MB) vs. high-sensitivity cardiac troponin (hs-cTn) in patients undergoing elective PCI. METHODS AND RESULTS: Between 2017 and 2021, periprocedural MI was assessed in a prospective study. The primary clinical outcome of interest was all-cause death at 1-year follow-up. A total of 1010 patients undergoing elective PCI were included. SCAI periprocedural MI based on CK-MB vs. hs-cTnI occurred in 1.8 and 13.5% of patients, respectively. hs-cTnI periprocedural MI in the absence of concomitant CK-MB criteria was associated with lower rates of ancillary criteria, including angiographic, ECG, and cardiac imaging criteria. At 1-year follow-up, periprocedural MI defined by CK-MB (adjusted hazard ratio, HR, 4.27, 95% confidence intervals, CI, 1.23-14.8; P = 0.022) but not hs-cTnI (adjusted HR 2.04, 95% CI 0.94-4.45; P = 0.072) was associated with a higher risk of all-cause death. Hs-cTnI periprocedural MI was not predictive of death unless accompanied by CK-MB criteria (adjusted HR 4.64, 95% CI 1.32-16.31; P = 0.017). CONCLUSION: In the setting of elective PCI, using hs-cTn instead of CK-MB resulted in a substantial increase in SCAI periprocedural MI events, which were not prognostically relevant in the absence of concurrent CK-MB elevations.
No takes yet. Share an insight, caveat, or question.
Piccolo et al. (2022) conducted a cohort in Elective percutaneous coronary intervention (PCI) (n=1,010). SCAI periprocedural MI based on hs-cTnI vs. SCAI periprocedural MI based on CK-MB was evaluated on All-cause death at 1-year follow-up (HR 2.04, 95% CI 0.94-4.45, p=0.072). Using hs-cTnI instead of CK-MB to define periprocedural MI increased event rates (13.5% vs 1.8%) but was not associated with 1-year mortality (HR 2.04; 95% CI 0.94-4.45; P=0.072).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: